PHILADELPHIA, PA — Virion Therapeutics, LLC announced that new clinical data from its VRON-0200 program for chronic Hepatitis B virus (HBV) infection will be featured in an oral presentation at the upcoming American Association for the Study of Liver Diseases (AASLD) Liver Meeting®, taking place November 7–10, 2025, in Washington, D.C. The company will also present new manufacturing data at the Vaccines Summit in Boston later in November.
The AASLD presentation will highlight long-term safety, tolerability, and clinical activity results from the Phase 1b trial of VRON-0200, including follow-up data in chronically HBV-infected patients. According to the company, this marks the first disclosure of extended post-dosing outcomes for the investigational immunotherapy.
“Chronic HBV infection affects close to 260 million people worldwide and contributes to almost 1 million deaths annually from liver-related complications,” said Dr. Andrew D. Luber, CEO of Virion Therapeutics. “To date, investigational treatments have failed to restore the immunity needed to control the virus, resulting in viral rebound, which is the Achilles heel of current HBV functional cure regimens. We look forward to sharing our latest findings at AASLD, including long-term follow-up responses that support VRON-0200’s potential to be the foundational backbone — the ‘spark’ — of a functional cure for chronic HBV.”
At the Liver Meeting, Dr. Grace Lai-Hung Wong of The Chinese University of Hong Kong will present “HBsAg declines observed with VRON-0200 alone are rapidly enhanced with the addition of combination antiviral therapies,” on Sunday, November 9, at 5:15 p.m. The data will explore how VRON-0200’s immunologic activity can be amplified when combined with antiviral regimens.
At the Vaccines Summit, Paula MacDonald, Chief Technology Officer of Virion Therapeutics, will discuss the application of a digital droplet polymerase chain reaction (ddPCR) assay for assessing VRON-0200’s physical and infectious titers—a key advancement in the company’s bioprocessing and manufacturing platform.
Chronic HBV remains a major global health challenge, with roughly 254 million individuals infected and 1.1 million annual deaths from liver complications. Despite the availability of a preventive vaccine, no curative treatment exists. Current standards of care rely on lifelong antiviral therapy to maintain viral suppression.
VRON-0200 is a therapeutic vaccine designed to induce immune control over HBV and ultimately achieve a functional cure. Early Phase 1b data show that a single intramuscular dose was safe, well tolerated, and capable of stimulating anti-HBV immune responses both as monotherapy and in combination with antiviral treatments.
The upcoming presentations highlight Virion Therapeutics’ progress in developing novel immunotherapies designed to address one of the most persistent unmet needs in global infectious disease.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.